Here's What Key Metrics Tell Us About Techne (TECH) Q4 Earnings

Techne (TECH) reported $316.96 million in revenue for the quarter ended June 2025, representing a year-over-year increase of 3.6%. EPS of $0.53 for the same period compares to $0.49 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $315.44 million, representing a surprise of +0.48%. The company delivered an EPS surprise of +6%, with the consensus EPS estimate being $0.50.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.Here is how Techne performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:Organic Growth: 3% versus the three-analyst average estimate of 3%.Organic Growth - Diagnostics and Spatial Biology: -1% versus 2.3% estimated by two analysts on average.Organic Growth - Protein Sciences: 4% versus the two-analyst average estimate of 2.7%.Net Sales- Intersegment revenue: $0.79 million compared to the $-0.5 million average estimate based on two analysts. The reported number represents a change of -225.3% year over year.Net Sales- Protein Sciences: $226.47 million versus the two-analyst average estimate of $224.65 million. The reported number represents a year-over-year change of +5.8%.Net Sales- Diagnostics and Spatial Biology: $89.71 million versus $92.75 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -1.1% change.View all Key Company Metrics for Techne here>>>Shares of Techne have returned +3.7% over the past month versus the Zacks S&P 500 composite's +0.5% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.Zacks' Research Chief Picks Stock Most Likely to "At Least Double"Our experts have revealed their Top 5 recommendations with money-doubling potential – and Director of Research Sheraz Mian believes one is superior to the others. Of course, all our picks aren’t winners but this one could far surpass earlier recommendations like Hims & Hers Health, which shot up +209%.See Our Top Stock to Double (Plus 4 Runners Up) >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Bio-Techne Corp (TECH): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks